China Suspends GSK Tender Qualification Under Dutasteride Ban
GSK becomes the second foreign pharma firm in recent months to be hit with a ban on the import, sale and use of a product by increasingly assertive Chinese regulatory authorities.
You may also be interested in...
Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.